Outlook Therapeutics Inc
41O
Company Profile
Business description
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
Contact
111 S. Wood Avenue
Suite 100
IselinNJ08852
USAT: +1 609 619-3990
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 September 2026
Employees
17
Stocks News & Analysis
stocks
Margins have bottomed for ASX listed consumer goods company
Impact of tariffs have been priced in.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,988.30 | 61.40 | -0.68% |
| CAC 40 | 8,338.80 | 61.31 | -0.73% |
| DAX 40 | 24,838.74 | 300.95 | -1.20% |
| Dow JONES (US) | 51,712.71 | 148.01 | 0.29% |
| FTSE 100 | 10,398.93 | 38.92 | -0.37% |
| HKSE | 23,336.28 | 432.24 | -1.82% |
| NASDAQ | 26,166.60 | 351.33 | -1.32% |
| Nikkei 225 | 69,788.38 | 2,565.58 | -3.55% |
| NZX 50 Index | 13,435.77 | 10.28 | -0.08% |
| S&P 500 | 7,472.79 | 27.79 | -0.37% |
| S&P/ASX 200 | 8,787.00 | 48.10 | -0.54% |
| SSE Composite Index | 4,106.25 | 56.85 | -1.37% |